Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.
Date
2024-06-29Author
Cheang, MCU
Rimawi, M
Johnston, S
Jacobs, SA
Bliss, J
Pogue-Geile, K
Kilburn, L
Zhu, Z
Schuster, EF
Xiao, H
Swaim, L
Deng, S
Lu, DR
Gauthier, E
Tursi, J
Slamon, DJ
Rugo, HS
Finn, RS
Liu, Y
Type
Journal Article
Metadata
Show full item recordAbstract
Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients with breast cancer and helps determine treatment. This study compared IBCMS methods on various gene-expression platforms in PALOMA-2 and PALLET trials. PALOMA-2 tumor samples were profiled using EdgeSeq and nanostring and subtyped with AIMS, PAM50, and research-use-only (ruo)Prosigna. PALLET tumor biopsies were profiled using mRNA sequencing and subtyped with AIMS and PAM50. In PALOMA-2 (n = 222), a 54% agreement was observed between results from AIMS and gold-standard ruoProsigna, with AIMS assigning 67% basal-like to HER2-enriched. In PALLET (n = 224), a 69% agreement was observed between results from PAM50 and AIMS. Different IBCMS methods may lead to different results and could misguide treatment selection; hence, a standardized clinical PAM50 assay and computational approach should be used.Trial number: NCT01740427.
Collections
Subject
Science & Technology
Life Sciences & Biomedicine
Oncology
DISTANT RECURRENCE
PAM50 RISK
TRIAL
TRASTUZUMAB
PREDICTOR
SCORE
Research team
Clin Trials & Stats Unit
Language
eng
Date accepted
2024-06-14
License start date
2024-06-29
Citation
npj Breast Cancer, 2024, 10 (1), pp. 54 -
Publisher
NATURE PORTFOLIO